



Supplementary Figure S5. Pharmacodynamic Changes in Biomarkers Over Time (A) and Changes By Best Overall Response (B) in All Study 114 Cohorts

Some results of the breast cancer cohort were also reported in Masuda N. et al, *Eur J Cancer*. 2022.

Asterisks indicate results of 1-sample Wilcoxon signed-rank test results of $P < 0.05$ (*), $P < 0.01$ (**), $P < 0.001$ (***), or $P < 0.0001$ (****).

C, cycle; D, day; ICAM, intercellular adhesion molecule; PECAM, platelet and endothelial cell adhesion molecule; TEK, TEK receptor tyrosine kinase; VEGFR, vascular endothelial growth factor receptor.